Eli Lilly and Company (LLY)

NYSE: LLY · USD

$1,290

+8.20 (+0.6%)· Recorded snapshot

영어 원본으로 대체KO

번역하는 동안 영어 원본을 표시 중

이 리포트는 아직 번역되지 않았습니다. 번역 대기열이 따라잡으면 몇 분 후에 새로고침하세요.

StockMarketAgent Research · Analyzed 2026-09-08

Our latest published analysis: LLY rated Sell

Eli Lilly and Company's published Sell conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$836 / share

Potential value

$1,052 / share

Upside to FV

-27.3%

from $1,290

Moat

1/10

None

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$1.02T
Revenue (ttm)	79.7B
Net income (ttm)	26.7B
EPS (ttm)	$29.8
Shares out	891.4M
P/E (trailing)	43.3x
P/E (forward)	24.6x
Dividend	$6.92 (0.53%)
Volume	1,523,010
Beta	0.45

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 79.7B
Net income (ttm): 26.7B
EPS (ttm): $29.8
P/E (trailing): 43.3x
P/E (forward): 24.6x
Market cap: $1.02T

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$28.32B	$28.54B	$34.12B	$45.04B	$65.18B	+23.2%
Gross profit	$21.01B	$21.91B	$27.04B	$36.62B	$54.62B	+27.0%
Operating income	$6.50B	$7.14B	$7.04B	$13.46B	$26.37B	+42.0%
Net income	$5.58B	$6.24B	$5.24B	$10.59B	$20.64B	+38.7%
EPS (diluted)	$8.17	$7.94	$6.32	$13.00	$24.21	+31.2%
EBITDA	$8.04B	$8.66B	$8.57B	$15.23B	$27.94B	+36.5%
R&D	$6.93B	$7.19B	$9.31B	$10.99B	$13.34B	+17.8%
SG&A	$6.14B	$6.07B	$6.94B	$8.13B	$11.09B	+15.9%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	31.1B	41.4x	6.4x	96.6%	+47.5%	-52.1%	적극 매수
ARGX	argenx SE	56.1B	31.5x	9.4x	57.0%	+63.3%	+7.5%	적극 매수
AXON	Axon Enterprise Inc.	34.4B	176.1x	10.6x	1.2%	+31.9%	-43.4%	매도
ABBV	AbbVie Inc.	505.6B	80.8x	7.9x	17.7%	+3.7%	+29.1%	매도
ABT	Abbott Laboratories	177.6B	38.2x	3.7x	7.2%	+2.7%	-17.2%	비중 축소
ALGN	Align Technology Inc.	10.9B	26.6x	2.6x	17.2%	+3.6%	+11.6%	비중 축소

Base and Bull scenarios

Base50%

Price target

$836.00

-27.3% from spot

The base path supports Fair value, but the report-date price remains above that estimate.

FY2026-FY2027 revenue and EPS follow the annual estimate path.
Growth fades after FY2027 while required reinvestment gradually declines.

Bull20%

Price target

$1,051.71

-8.5% from spot

Upside persists only if stronger growth also improves margins and cash without creating a permanent maintenance burden.

FY2027 EPS reaches the upper analyst estimate range.
Product growth absorbs costs and capital spending converts into productive capacity.

Sensitivity: Ke × terminal growth

The highlighted cell is Fair value when every assumption sits at its base level ($836.00). Each row and column shows what Fair value becomes when one assumption moves.

Ke ↓ / g →	2.5%	3.0%	3.5%	4.0%	4.5%
5.8%	$1,020	$1,105	$1,238	$1,479	$2,124
6.8%	$875	$916	$972	$1,051	$1,175
7.8%	$782	$806	$836	$875	$927
8.8%	$716	$731	$749	$771	$799
9.8%	$664	$674	$686	$701	$718

Scorecard

Published factor rows and weighted composite

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E24.6

P25 n/aP50 n/aP75 n/a

Trailing P/E38.6

P25 n/aP50 n/aP75 n/a

ROE102.3

P25 n/aP50 n/aP75 n/a

ROIC42.2

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All LLY indicators

Market & fundamental data

Available fields

294

Groups with data

Currency

USD

Showing 294 of 294 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0000059478
Company name	Eli Lilly and Company
Country	United States
Country code	US
CUSIP number	532457108
Earnings date	2026-10-29
Earnings time	bmo
Employees	50,000
Employees change	3,000
Employees growth	6.38%
Enterprise value	$1.2T
Exchange	NYSE
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1876
In index	SP500
Industry	Drug Manufacturers - General
Is primary listing	Yes
Is SPAC	No
ISIN number	US5324571083
Last 10-K release date	2026-02-12
Last earnings date	2026-08-05
Last refreshed	2026-10-28
Last stock split date	1997-10-16
Last stock split type	Forward
Market cap	$1.1T
Market cap category	Mega-Cap
Next earnings date	2026-10-29
Options	Yes
Price	$1,290.07
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	LLY
Tags	pharmaceuticals, weight-loss
U.S. state	Indiana
Website	https://www.lilly.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	40.97x
Average P/E ratio (10Y)	52.78x
Average P/E ratio (3Y)	71.41x
Average P/E ratio (5Y)	62.99x
Earnings yield	2.31%
EV/Earnings	45.02x
EV/EBIT	30.36x
EV/EBITDA	28.83x
EV/FCF	66.11x
EV/Sales	15.09x
FCF / EV yield	1.51%
FCF yield	1.57%
Forward EV/Sales	12.73x
Forward P/E	33.53x
Forward P/S	12.25x
Graham number	159.59685
Graham upside	-87.71%
Industry forward P/E	18.51x
Industry P/E	35.9x
Lynch fair value	$744.73
Lynch upside	-42.64%
P/(FCF - SBC) ratio	65.98x
P/(OCF - SBC) ratio	42.19x
P/B ratio	33.73x
P/E ratio	43.31x
P/FCF ratio	63.62x
P/OCF ratio	41.21x
P/S ratio	14.53x
PEG ratio	1.6x
Price / tangible book value	167.25x
Price/EBITDA ratio	27.75x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	49.72%
EBITDA margin	52.35%
Effective tax rate	20.49%
FCF margin	22.83%
Gross margin	83.4%
Operating margin	49.72%
Pretax margin	42.17%
Profit margin	33.53%
Profit per employee	$534,220
Profitable quarters	11
Profitable years	8
Revenue per employee	$1.6M
ROA	20.36%
ROA (5Y)	13.51%
ROCE	41.89%
ROE	102.29%
ROE (5Y)	74.21%
ROIC	42.24%
ROIC (5Y)	35.51%
SBC / revenue	0.81%
Tax / revenue	8.64%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	94.8%
EPS growth (Q)	26.23%
EPS growth (QoQ)	-3.87%
EPS growth 10Y	29.08%
EPS growth 3Y	60.68%
EPS growth 5Y	34.97%
EPS growth quarters	11
EPS growth years	2
FCF growth	272.37%
FCF growth (Q)	458.06%
FCF growth (QoQ)	157.96%
FCF growth 3Y	69.77%
FCF growth 5Y	26.73%
Gross profit growth	50.96%
Gross profit growth (Q)	50.31%
Gross profit growth 3Y	42.51%
Gross profit growth 5Y	26.7%
Net income growth	93.56%
Net income growth (Q)	25.33%
Net income growth (QoQ)	-4.07%
Net income growth 3Y	60.19%
Net income growth 5Y	34.49%
Net income growth quarters	11
Net income growth years	2
OCF growth	156.73%
OCF growth (Q)	246.29%
OCF growth (QoQ)	100.45%
OCF growth 10Y	23.94%
OCF growth 3Y	65.09%
OCF growth 5Y	31.67%
Operating income growth	78.34%
Operating income growth (Q)	77.42%
Operating income growth 3Y	68.37%
Operating income growth 5Y	38.93%
Revenue growth	49.58%
Revenue growth (Q)	47.67%
Revenue growth (QoQ)	16.04%
Revenue growth 10Y	14.48%
Revenue growth 3Y	39.23%
Revenue growth 5Y	24.41%
Revenue growth quarters	13
Revenue growth years	8

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-9.9B
Depreciation and amortization	$2.1B
EBIT	$39.6B
EBITDA	$41.7B
EPS	$29.79
FCF per share	$20.41
Financing cash flow	$2.6B
Free cash flow	$18.2B
Free cash flow minus SBC	$17.5B
Gross profit	$66.4B
Income taxes	$6.9B
Investing cash flow	$-25.1B
Net borrowing	$15.2B
Net cash flow	$5.6B
Net income	$26.7B
Operating cash flow minus SBC	$27.4B
Operating income	$39.6B
Revenue	$79.7B
Stock-based compensation	$649M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	6.55
Book value per share	$38.00
Debt / EBITDA	1.31
Debt / equity	1.62
Debt / FCF	3.02
Goodwill	$8.8B
Interest coverage	215.26
Long-term assets	$77.6B
Long-term liabilities	$60.7B
Net cash (debt)	$-45.2B
Net cash / market cap	-3.9%
Net debt / EBITDA	1.08
Net debt / equity	1.33
Net debt / FCF	2.48
Piotroski F-Score	7
Property, plant and equipment	$29.3B
Shareholders' equity	$33.9B
Tangible book value	$6.9B
Tangible book value per share	$7.76
Total assets	$142.3B
Total cash	$9B
Total debt	$54.9B
Total liabilities	$108.4B
WACC	6.45%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.66
Current assets	$64.7B
Current liabilities	$47.7B
Current ratio	1.35
Inventory turnover	0.95
Net working capital	$15B
Quick ratio	0.68
Working capital	$16.9B
Working capital turnover	5.74

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	0.62%
Dividend growth	15.33%
Dividend growth (10Y)	12.99%
Dividend growth (3Y)	15.25%
Dividend growth (5Y)	15.27%
Dividend growth years	11
Dividend payment date	2026-12-10
Dividend payment years	56
Dividend payout frequency	Quarterly
Dividend per share	$6.92
Dividend yield	0.53%
Ex-dividend date	2026-11-13
FCF payout ratio	33.91%
Last dividend	$1.73
Payout ratio	23.23%
Shareholder yield	1.15%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	1,597.24%
10Y return CAGR	34.83%
10Y total return	1,884.75%
150-day SMA	$1,112.50
15Y price change	3,313.31%
15Y return CAGR	29.36%
15Y total return	4,652.84%
1D price change	0.64%
1M price change	9.22%
1M total return	9.22%
1W price change	0.7%
1W total return	0.7%
1Y price change	56.41%
1Y return CAGR	57.45%
1Y total return	57.4%
20-day SMA	$1,221.30
200-day SMA	$1,088.06
20Y price change	2,166.56%
20Y return CAGR	20.23%
20Y total return	3,880.39%
3M price change	7.94%
3M total return	8.1%
3Y price change	130.73%
3Y return CAGR	33.04%
3Y total return	135.53%
50-day SMA	$1,191.90
50-day SMA vs 200-day SMA	50over200
52-week high	$1,321.21
52-week high date	2026-10-22
52-week low	$809.63
52-week low date	2025-10-29
5Y price change	416.7%
5Y return CAGR	40.16%
5Y total return	440.69%
6M price change	48.87%
6M total return	49.34%
All-time high	$1,321.21
All-time high date	2026-10-22
All-time low	$2.04
All-time low date	1977-09-21
Average true range (ATR)	$36.56
Average volume	2.2M
Beta (1Y)	-0.01
Beta (2Y)	0.43
Beta (5Y)	0.45
Change from 52-week high	-2.36%
Change from 52-week low	59.34%
Change from all-time high	-2.16%
Change from all-time low	63,294.8%
Change from open	2.05%
Day's gap	-1.38%
Dollar volume	$2B
High price	$1,299.00
Low price	$1,260.97
Monthly RSI	69.86
Open price	$1,264.21
Position in 52-week range	76.52%
Premarket change	-0.93%
Premarket close	$1,281.91
Premarket price	$1,270.00
Premarket volume	15.2K
Previous close	$1,281.91
Price vs 150-day SMA	16.19%
Price vs 20-day SMA	5.84%
Price vs 200-day SMA	18.8%
Price vs 50-day SMA	8.45%
Relative volume	0.69
RSI	65.09
Sharpe ratio	1.36
Sharpe ratio (3Y)	0.84
Sharpe ratio (5Y)	1.09
Sortino ratio	2.49
Sortino ratio (3Y)	1.42
Sortino ratio (5Y)	1.88
Volume	1.5M
Weekly RSI	65.05
YTD price change	20.28%
YTD total return	20.86%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	888.9M
Float percentage	99.73%
Shares change (QoQ)	-0.25%
Shares change (YoY)	-0.62%
Shares held by insiders	0.17%
Shares held by institutions	89.36%
Shares outstanding	891.4M
Short % of float	0.79%
Short % of shares	0.79%
Short ratio	3 days

Other indicators

Additional ticker metrics that do not fit the primary research groupings.

Metric	Value
Page views	1,004

Deeper analysis on LLY

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Quote this valuation with its source: Fair value, Potential value and the price at analysis.

Frequently asked questions

About this LLY report

What is the latest published LLY stock rating?

Eli Lilly and Company is shown with Sell in the latest published report, analyzed 2026-09-08. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full LLY analysis?

The full latest published report, analyzed 2026-09-08, lives at /stocks/LLY/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for LLY?

The latest published report analyzed 2026-09-08 gives LLY a fair value of USD 836 and a potential value of USD 1,052. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the LLY page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-09-08). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

SellLLY · Fair value $836-27.3%

Read full analysis →

Eli Lilly and Company (LLY)

Our latest published analysis: LLY rated Sell

Price

Financial snapshot

Fair-value bridge

Latest news · LLY

Valuation

Profitability

Balance sheet

Trading

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

All LLY indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Other indicators

Deeper analysis on LLY

Frequently asked questions

등급 이력

Category	Score	Reading
Valuation	1.5
Management	7.5
Balance Sheet	3.5
Profitability	8.5
Revenue Growth	9.0
Risk Assessment	7.0
Competitive Moat	1.0
Earnings Quality	7.5
Capital Efficiency	8.5